These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 930742)

  • 1. The on-off effect in Parkinson's disease treated with levodopa with remarks concerning the effect of sleep.
    Clark EC; Feinstein B
    Adv Exp Med Biol; 1977; 90():175-82. PubMed ID: 930742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonergic mechanisms in levodopa-induced "on-off" and sleep disorders in Parkinson's disease.
    Sandyk R
    Int J Neurosci; 1988 Dec; 43(3-4):207-13. PubMed ID: 3243678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
    Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A;
    Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
    Hironishi M; Miwa H; Kondo T
    No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A clinical, pharmacologic, and polysomnographic study of sleep benefit in Parkinson's disease.
    Högl BE; Gómez-Arévalo G; García S; Scipioni O; Rubio M; Blanco M; Gershanik OS
    Neurology; 1998 May; 50(5):1332-9. PubMed ID: 9595983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Efficacy Profile of Rotigotine During the Waking Hours in Patients With Advanced Parkinson's Disease: A Post Hoc Analysis.
    LeWitt PA; Poewe W; Elmer LW; Asgharnejad M; Boroojerdi B; Grieger F; Bauer L
    Clin Neuropharmacol; 2016; 39(2):88-93. PubMed ID: 26882318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
    Shoulson I; Oakes D; Fahn S; Lang A; Langston JW; LeWitt P; Olanow CW; Penney JB; Tanner C; Kieburtz K; Rudolph A;
    Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off.
    Koller W; Guarnieri M; Hubble J; Rabinowicz AL; Silver D
    J Neural Transm (Vienna); 2005 Feb; 112(2):221-30. PubMed ID: 15503197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial.
    Hauser RA; Olanow CW; Kieburtz KD; Pourcher E; Docu-Axelerad A; Lew M; Kozyolkin O; Neale A; Resburg C; Meya U; Kenney C; Bandak S
    Lancet Neurol; 2014 Aug; 13(8):767-76. PubMed ID: 25008546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of cabergoline added to levodopa treatment on sleep-wake cycle in idiopathic Parkinson's disease: an open label 24-hour polysomnographic study.
    Romigi A; Stanzione P; Marciani MG; Izzi F; Placidi F; Cervellino A; Giacomini P; Brusa L; Grossi K; Pierantozzi M
    J Neural Transm (Vienna); 2006 Dec; 113(12):1909-13. PubMed ID: 16736238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term experience with selegiline and levodopa in Parkinson's disease.
    Lieberman A
    Neurology; 1992 Apr; 42(4 Suppl 4):32-6; discussion 41-8. PubMed ID: 1584430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beginning-of-dose motor deterioration following the acute administration of levodopa and apomorphine in Parkinson's disease.
    Merello M; Lees AJ
    J Neurol Neurosurg Psychiatry; 1992 Nov; 55(11):1024-6. PubMed ID: 1469397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.
    Montastruc JL; Rascol O; Senard JM; Rascol A
    J Neurol Neurosurg Psychiatry; 1994 Sep; 57(9):1034-8. PubMed ID: 8089666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sleep benefit in Parkinson's disease.
    Merello M; Hughes A; Colosimo C; Hoffman M; Starkstein S; Leiguarda R
    Mov Disord; 1997 Jul; 12(4):506-8. PubMed ID: 9251067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute homocysteine rise after repeated levodopa application in patients with Parkinson's disease.
    Müller T; Muhlack S
    Parkinsonism Relat Disord; 2010 Dec; 16(10):688-9. PubMed ID: 20719554
    [No Abstract]   [Full Text] [Related]  

  • 17. Low-dose, slow-increase bromocriptine in patients with progressive Parkinson's disease and complications of levodopa therapy.
    Stern MB; Vernon GM; Gollomp SM; Hurtig HI
    Bull Clin Neurosci; 1986; 51():52-6. PubMed ID: 3455244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Motor complications in patients with Parkinson disease treated with levodopa].
    Luquin MR; Obeso JA; Martínez-Lage JM
    Neurologia; 1989; 4(1):4-11. PubMed ID: 2631806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Force overflow and levodopa-induced dyskinesias in Parkinson's disease.
    Wenzelburger R; Zhang BR; Pohle S; Klebe S; Lorenz D; Herzog J; Wilms H; Deuschl G; Krack P
    Brain; 2002 Apr; 125(Pt 4):871-9. PubMed ID: 11912119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychiatric complications of levodopa therapy of Parkinson's disease.
    Nausieda PA; Glantz R; Weber S; Baum R; Klawans HL
    Adv Neurol; 1984; 40():271-7. PubMed ID: 6695603
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.